Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Depreciation & Amortization (CF) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $145000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 58.33% to $145000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $445000.0 through Dec 2025, down 48.97% year-over-year, with the annual reading at $445000.0 for FY2025, 48.97% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $145000.0 at Plus Therapeutics, up from $77000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $348000.0 in Q4 2024, with the low at $77000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $156000.0, with a median of $155000.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) soared 130.46% in 2024, then crashed 61.31% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $88000.0 in 2021, then surged by 80.68% to $159000.0 in 2022, then decreased by 5.03% to $151000.0 in 2023, then skyrocketed by 130.46% to $348000.0 in 2024, then plummeted by 58.33% to $145000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $145000.0, $77000.0, and $77000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.